Fulgent Genetics, Inc.
For the period ended Mar 31, 2026. Filed May 1, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 1, 2026
FLGT$25.78-1.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Comprehensive Loss
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Net loss from consolidated operations | $(25,274) | $(11,899) |
| Other comprehensive income (loss): | ||
| Foreign currency translation income | 240 | 109 |
| Net (loss) gain on available-for-sale debt securities, net of tax | (3,149) | 4,624 |
| Net comprehensive loss from consolidated operations | (28,183) | (7,166) |
| Net loss attributable to noncontrolling interest | 448 | 369 |
| Foreign currency translation income attributable to noncontrolling interest | (67) | (30) |
| Comprehensive loss attributable to noncontrolling interest | 381 | 339 |
| Comprehensive loss attributable to Fulgent | $(27,802) | $(6,827) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.